Indium 111

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform

Paul E Di Cesare - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of combined technetium 99m sulfur colloid Indium 111 leukocyte scans to detect infected total hip and knee arthroplasties
    Journal of Arthroplasty, 2001
    Co-Authors: Thomas N Joseph, Mohammed Mujtaba, Andrew L Chen, Stephen L Maurer, Joseph D Zuckerman, Catherine Maldjian, Paul E Di Cesare
    Abstract:

    Abstract The reliability of combined Indium-111 leukocyte/technetium-99m sulfur colloid scans, with and without the addition of blood pooling and blood flow studies, in the diagnosis of infected total joint arthroplasty was investigated. Both scans were performed on 58 patients before reoperation of total hip or knee arthroplasty in the period 1996–1999. Results for imaging alone included 100% specificity, 46% sensitivity, 100% positive predictive value, 84% negative predictive value, and 88% accuracy. Inclusion of blood pooling and flow phase data improved results to 66% sensitivity, 89% negative predictive value, and 90% accuracy, with reductions in specificity (98%) and positive predictive value (91%). Routine use of these radionuclide scans is not supported by these data.

Wouter A P Breeman - One of the best experts on this subject based on the ideXlab platform.

  • d lysine reduction of Indium 111 octreotide and yttrium 90 octreotide renal uptake
    The Journal of Nuclear Medicine, 1997
    Co-Authors: Bert F Bernard, Edgar J Rolleman, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning, Helmut R Macke, M De Jong
    Abstract:

    Indium-111-DTPA-octreotide (111In-DTPAOC) is used successfully for imaging somatostatin receptor-positive lesions. A new and promising application is its use in peptide-receptor radionuclide therapy (PRRT). For the latter purpose, [DOTA0, D-Phe1, Ty3]octreotide (DOTATOC), which is suitable for stable radiolabeling with 90Y, is probably even more promising. Significant renal uptake of these octreotide analogs exists, however, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and limiting the possibilities for PRRT. We showed that the renal uptake of 111In-DTPAOC could be reduced to about 50% of control by L-lysine administration in vivo in rats. This study compares the effects of several doses and different methods of administration of D-and L-lysine, in addition to time-related effects of D-lysine, on kidney uptake of 111In-DTPAOC and 90Y-DOTATOC. Methods: Male Wistar rats (200–250 g) were given 111In-DTPAOC (0.2 MBq, 0.5 µg-0.5 mg intravenously, intraperitoneally or orally) in the presence or absence of D-or L-lysine. At 1, 4 or 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. In different experiments, male Wistar rats (200–250 g) were given 90Y-DOTATOC (1 MBq, 0.5 µg intravenously) in the presence or absence of D-lysine. At 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. Results: Administration of D-or L-lysine in a single intravenous dose of 400 mg/kg, resulted in more than 50% inhibition of kidney uptake of111In-DTPAOC at all time points tested, independently of the mass of 111In-DTPAOC used. Higher or repeated doses of lysine did not give a significantly higher percentage inhibition. D-lysine, given orally in a dose of 400 mg/kg at 30 or 15 min before 111In-DTPAOC injection, resulted in 30% and 20% inhibition of kidney uptake, respectively. L-lysine, given orally 30 min before 111In-DTPAOC administration, resulted in 30% inhibition as well. Inhibition of kidney uptake of 111In-DTPAOC by L-lysine after intraperitoneal administration was 40%. After L-lysine administration, 111In-DTPAOC was decreased in the kidneys and in somatostatin receptor-positive organs such as the pancreas and adrenal glands. In contrast, D-lysine did not have a significant effect on uptake in octreotide receptor-positive organs. Renal uptake of 90Y-DOTATOC was reduced by 65% by intravenous D-lysine, whereas radioactivity in blood, pancreas and adrenal glands was not affected. Conclusion: D-lysine may be preferred to L-lysine for reduction of renal uptake of radioactivity during scintigraphy and PRRT because of its lower toxicity and because it should not interfere with the natural amino acid metabolic balance.

  • inhibition of renal uptake of Indium 111 dtpa octreotide in vivo
    The Journal of Nuclear Medicine, 1996
    Co-Authors: M De Jong, Edgar J Rolleman, Bert F Bernard, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning
    Abstract:

    Indium-111-DTPA-octreotide has been successfully used for imaging of somatostatin receptor-positive lesions. However, significant renal uptake of 111 In-DTPA-octreotide exists, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and the possibilities for radiotherapy. The aim of the present study was to determine whether renal uptake of 'In-DTPA-octreotide could be reduced in vivo in rats. Methods : Male Wistar rats (200-250 g) were placed in metabolic cages and injected with 111 In-DTPA-octreotide (0.2 MBq and 0.5 μg octreotide), in the presence or absence of re-uptake blockers. At time t = 20 hr after injection, rats were sacrificed and organs were isolated and counted for radioactivity. Results : Adding NH 4 Cl or NaHCO 3 to the food, resulting in the production of more acid or alkaline urine respectively, resulted in less radioactivity in the kidneys 20 hr after injection compared to controls. Lysine in a single dose of 400 mg/kg resulted in an inhibition of kidney uptake of 40%. When lysine was injected 30 min before 111 In-DTPA-octreotide, the inhibition was 25%. Arginine had less effect on tubular uptake of 111 In-DTPA-octreotide than lysine (20% inhibition). Sodium maleate inhibited kidney uptake of 111 In-DTPA-octreotide most successfully. Acetazolamide (100 mg/kg), succinylacetone (100 mg/kg), cystine dimethylester (340 mg/kg) and increase in urinary flow did not influence 111 In-DTPA-octreotide retention in the kidneys. Conclusion : It appeared possible to reduce re-uptake of 111 In-DTPA-octreotide in the rat kidney in vivo. The most pronounced effects were seen after administration of sodium maleate or lysine but, because of the described toxic effects of maleate, we will study further only the effects of lysine in a clinical setting.

  • in vitro and in vivo studies of substance p receptor expression in rats with the new analog Indium 111 dtpa arg1 substance p
    The Journal of Nuclear Medicine, 1996
    Co-Authors: Wouter A P Breeman, Willem H Bakker, M P Vanhagen, H A Visserwisselaar, M Van Der Pluijm, Jan W Koper, B Setyonohan, D J Kwekkeboom, M P Hazenberg, S W J Lamberts
    Abstract:

    We evaluated the potential usefulness of a new radiolabeled substance P (SP) analog, [ 111 ln-DTPA-Arg 1 ]SP, as a radiopharmaceutical for the in vivo detection of SP receptor-positive (SPR+) immunologic disorders (i.e., inflammatory bowel disease and arthritis) and tumors (i.e., carcinoid). Methods : Substance P, [DTPA-Arg 1 ]SP and [3-(p-hydroxyphenyl)propionyl-Arg 1 ]SP (Bolton-Hunter-SP, [BH-SP]) were tested as competitors for 125 I-BH-SP to SPR in rat brain cortex membranes. An autoradiographic displacement study of the submandibular gland of the rat with the 125 I-BH-SP as radioligand and [DTPA-Arg 1 ]SP as competitor was performed. Tissue distribution and ex vivo autoradiography were studied in rats, with and without pretreatment with the selective nonpeptide antagonist CP96,345 to quantify specific binding. In vivo metabolism of [ 111 ln-DTPA-Arg 1 ]SP was performed in control rats. Gamma-camera scintigraphic studies were carried out with control rats to visualize the SPR+ salivary glands in rats bearing the SPR+ transplantable pancreatic tumor CA20948 and in rats with SPR+ adjuvant arthritic joints, which was induced after injection of a homogenate of Mycobacterium tuberculosis. Results : Substance P, [DTPA-Arg 1 ]SP and BH-SP dose-dependently inhibited binding of 125 I-BH-SP to SPR in rat brain cortex membranes with IC 50 values of 0.2, 4 and 2 nM, respectively. In an autoradiographic displacement study of the submandibular gland with 125 I-BH-SP as radioligand, an IC 50 of 2.7 nM was found for [DTPA-Arg 1 ]SP. In vivo metabolism of the radiopharmaceutical in the rat revealed a renal clearance rate of 50% of the injected radioactive dose in 30 min and a rapid enzymatic degradation of the radiopharmaceutical, resulting in an effective half-life of the intact radiopharmaceutical in blood of approximately 3 min. Tissue distribution and ex vivo autoradiographic studies in rats showed uptake and specific binding of radioactivity in isolated tumors and submandibular and parotid glands. Optimum SPR+ target-to-background ratios were found 24 hr after injection of [ 111 ln-DTPA-Arg 1 ]SP. Visualization of normal SPR+ tissues, such as the salivary glands by gamma camera scintigraphy, after administration of [ 111 ln-DTPA-Arg 1 ]SP was demonstrated in untreated rats. Pathological SPR+ processes were visualized both in rats bearing the transplantable pancreatic tumor CA20948 and in those with adjuvant mycobacteria tuberculosis-induced arthritic joints. Conclusion : [Indium-111-DTPA-Arg 1 ]SP can be used successfully to visualize SPR+ processes in vivo by gamma camera scintigraphy.

M De Jong - One of the best experts on this subject based on the ideXlab platform.

  • d lysine reduction of Indium 111 octreotide and yttrium 90 octreotide renal uptake
    The Journal of Nuclear Medicine, 1997
    Co-Authors: Bert F Bernard, Edgar J Rolleman, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning, Helmut R Macke, M De Jong
    Abstract:

    Indium-111-DTPA-octreotide (111In-DTPAOC) is used successfully for imaging somatostatin receptor-positive lesions. A new and promising application is its use in peptide-receptor radionuclide therapy (PRRT). For the latter purpose, [DOTA0, D-Phe1, Ty3]octreotide (DOTATOC), which is suitable for stable radiolabeling with 90Y, is probably even more promising. Significant renal uptake of these octreotide analogs exists, however, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and limiting the possibilities for PRRT. We showed that the renal uptake of 111In-DTPAOC could be reduced to about 50% of control by L-lysine administration in vivo in rats. This study compares the effects of several doses and different methods of administration of D-and L-lysine, in addition to time-related effects of D-lysine, on kidney uptake of 111In-DTPAOC and 90Y-DOTATOC. Methods: Male Wistar rats (200–250 g) were given 111In-DTPAOC (0.2 MBq, 0.5 µg-0.5 mg intravenously, intraperitoneally or orally) in the presence or absence of D-or L-lysine. At 1, 4 or 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. In different experiments, male Wistar rats (200–250 g) were given 90Y-DOTATOC (1 MBq, 0.5 µg intravenously) in the presence or absence of D-lysine. At 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. Results: Administration of D-or L-lysine in a single intravenous dose of 400 mg/kg, resulted in more than 50% inhibition of kidney uptake of111In-DTPAOC at all time points tested, independently of the mass of 111In-DTPAOC used. Higher or repeated doses of lysine did not give a significantly higher percentage inhibition. D-lysine, given orally in a dose of 400 mg/kg at 30 or 15 min before 111In-DTPAOC injection, resulted in 30% and 20% inhibition of kidney uptake, respectively. L-lysine, given orally 30 min before 111In-DTPAOC administration, resulted in 30% inhibition as well. Inhibition of kidney uptake of 111In-DTPAOC by L-lysine after intraperitoneal administration was 40%. After L-lysine administration, 111In-DTPAOC was decreased in the kidneys and in somatostatin receptor-positive organs such as the pancreas and adrenal glands. In contrast, D-lysine did not have a significant effect on uptake in octreotide receptor-positive organs. Renal uptake of 90Y-DOTATOC was reduced by 65% by intravenous D-lysine, whereas radioactivity in blood, pancreas and adrenal glands was not affected. Conclusion: D-lysine may be preferred to L-lysine for reduction of renal uptake of radioactivity during scintigraphy and PRRT because of its lower toxicity and because it should not interfere with the natural amino acid metabolic balance.

  • inhibition of renal uptake of Indium 111 dtpa octreotide in vivo
    The Journal of Nuclear Medicine, 1996
    Co-Authors: M De Jong, Edgar J Rolleman, Bert F Bernard, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning
    Abstract:

    Indium-111-DTPA-octreotide has been successfully used for imaging of somatostatin receptor-positive lesions. However, significant renal uptake of 111 In-DTPA-octreotide exists, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and the possibilities for radiotherapy. The aim of the present study was to determine whether renal uptake of 'In-DTPA-octreotide could be reduced in vivo in rats. Methods : Male Wistar rats (200-250 g) were placed in metabolic cages and injected with 111 In-DTPA-octreotide (0.2 MBq and 0.5 μg octreotide), in the presence or absence of re-uptake blockers. At time t = 20 hr after injection, rats were sacrificed and organs were isolated and counted for radioactivity. Results : Adding NH 4 Cl or NaHCO 3 to the food, resulting in the production of more acid or alkaline urine respectively, resulted in less radioactivity in the kidneys 20 hr after injection compared to controls. Lysine in a single dose of 400 mg/kg resulted in an inhibition of kidney uptake of 40%. When lysine was injected 30 min before 111 In-DTPA-octreotide, the inhibition was 25%. Arginine had less effect on tubular uptake of 111 In-DTPA-octreotide than lysine (20% inhibition). Sodium maleate inhibited kidney uptake of 111 In-DTPA-octreotide most successfully. Acetazolamide (100 mg/kg), succinylacetone (100 mg/kg), cystine dimethylester (340 mg/kg) and increase in urinary flow did not influence 111 In-DTPA-octreotide retention in the kidneys. Conclusion : It appeared possible to reduce re-uptake of 111 In-DTPA-octreotide in the rat kidney in vivo. The most pronounced effects were seen after administration of sodium maleate or lysine but, because of the described toxic effects of maleate, we will study further only the effects of lysine in a clinical setting.

Thomas N Joseph - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of combined technetium 99m sulfur colloid Indium 111 leukocyte scans to detect infected total hip and knee arthroplasties
    Journal of Arthroplasty, 2001
    Co-Authors: Thomas N Joseph, Mohammed Mujtaba, Andrew L Chen, Stephen L Maurer, Joseph D Zuckerman, Catherine Maldjian, Paul E Di Cesare
    Abstract:

    Abstract The reliability of combined Indium-111 leukocyte/technetium-99m sulfur colloid scans, with and without the addition of blood pooling and blood flow studies, in the diagnosis of infected total joint arthroplasty was investigated. Both scans were performed on 58 patients before reoperation of total hip or knee arthroplasty in the period 1996–1999. Results for imaging alone included 100% specificity, 46% sensitivity, 100% positive predictive value, 84% negative predictive value, and 88% accuracy. Inclusion of blood pooling and flow phase data improved results to 66% sensitivity, 89% negative predictive value, and 90% accuracy, with reductions in specificity (98%) and positive predictive value (91%). Routine use of these radionuclide scans is not supported by these data.

Willem H Bakker - One of the best experts on this subject based on the ideXlab platform.

  • d lysine reduction of Indium 111 octreotide and yttrium 90 octreotide renal uptake
    The Journal of Nuclear Medicine, 1997
    Co-Authors: Bert F Bernard, Edgar J Rolleman, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning, Helmut R Macke, M De Jong
    Abstract:

    Indium-111-DTPA-octreotide (111In-DTPAOC) is used successfully for imaging somatostatin receptor-positive lesions. A new and promising application is its use in peptide-receptor radionuclide therapy (PRRT). For the latter purpose, [DOTA0, D-Phe1, Ty3]octreotide (DOTATOC), which is suitable for stable radiolabeling with 90Y, is probably even more promising. Significant renal uptake of these octreotide analogs exists, however, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and limiting the possibilities for PRRT. We showed that the renal uptake of 111In-DTPAOC could be reduced to about 50% of control by L-lysine administration in vivo in rats. This study compares the effects of several doses and different methods of administration of D-and L-lysine, in addition to time-related effects of D-lysine, on kidney uptake of 111In-DTPAOC and 90Y-DOTATOC. Methods: Male Wistar rats (200–250 g) were given 111In-DTPAOC (0.2 MBq, 0.5 µg-0.5 mg intravenously, intraperitoneally or orally) in the presence or absence of D-or L-lysine. At 1, 4 or 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. In different experiments, male Wistar rats (200–250 g) were given 90Y-DOTATOC (1 MBq, 0.5 µg intravenously) in the presence or absence of D-lysine. At 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. Results: Administration of D-or L-lysine in a single intravenous dose of 400 mg/kg, resulted in more than 50% inhibition of kidney uptake of111In-DTPAOC at all time points tested, independently of the mass of 111In-DTPAOC used. Higher or repeated doses of lysine did not give a significantly higher percentage inhibition. D-lysine, given orally in a dose of 400 mg/kg at 30 or 15 min before 111In-DTPAOC injection, resulted in 30% and 20% inhibition of kidney uptake, respectively. L-lysine, given orally 30 min before 111In-DTPAOC administration, resulted in 30% inhibition as well. Inhibition of kidney uptake of 111In-DTPAOC by L-lysine after intraperitoneal administration was 40%. After L-lysine administration, 111In-DTPAOC was decreased in the kidneys and in somatostatin receptor-positive organs such as the pancreas and adrenal glands. In contrast, D-lysine did not have a significant effect on uptake in octreotide receptor-positive organs. Renal uptake of 90Y-DOTATOC was reduced by 65% by intravenous D-lysine, whereas radioactivity in blood, pancreas and adrenal glands was not affected. Conclusion: D-lysine may be preferred to L-lysine for reduction of renal uptake of radioactivity during scintigraphy and PRRT because of its lower toxicity and because it should not interfere with the natural amino acid metabolic balance.

  • inhibition of renal uptake of Indium 111 dtpa octreotide in vivo
    The Journal of Nuclear Medicine, 1996
    Co-Authors: M De Jong, Edgar J Rolleman, Bert F Bernard, T J Visser, Willem H Bakker, Wouter A P Breeman, Eric P Krenning
    Abstract:

    Indium-111-DTPA-octreotide has been successfully used for imaging of somatostatin receptor-positive lesions. However, significant renal uptake of 111 In-DTPA-octreotide exists, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and the possibilities for radiotherapy. The aim of the present study was to determine whether renal uptake of 'In-DTPA-octreotide could be reduced in vivo in rats. Methods : Male Wistar rats (200-250 g) were placed in metabolic cages and injected with 111 In-DTPA-octreotide (0.2 MBq and 0.5 μg octreotide), in the presence or absence of re-uptake blockers. At time t = 20 hr after injection, rats were sacrificed and organs were isolated and counted for radioactivity. Results : Adding NH 4 Cl or NaHCO 3 to the food, resulting in the production of more acid or alkaline urine respectively, resulted in less radioactivity in the kidneys 20 hr after injection compared to controls. Lysine in a single dose of 400 mg/kg resulted in an inhibition of kidney uptake of 40%. When lysine was injected 30 min before 111 In-DTPA-octreotide, the inhibition was 25%. Arginine had less effect on tubular uptake of 111 In-DTPA-octreotide than lysine (20% inhibition). Sodium maleate inhibited kidney uptake of 111 In-DTPA-octreotide most successfully. Acetazolamide (100 mg/kg), succinylacetone (100 mg/kg), cystine dimethylester (340 mg/kg) and increase in urinary flow did not influence 111 In-DTPA-octreotide retention in the kidneys. Conclusion : It appeared possible to reduce re-uptake of 111 In-DTPA-octreotide in the rat kidney in vivo. The most pronounced effects were seen after administration of sodium maleate or lysine but, because of the described toxic effects of maleate, we will study further only the effects of lysine in a clinical setting.

  • in vitro and in vivo studies of substance p receptor expression in rats with the new analog Indium 111 dtpa arg1 substance p
    The Journal of Nuclear Medicine, 1996
    Co-Authors: Wouter A P Breeman, Willem H Bakker, M P Vanhagen, H A Visserwisselaar, M Van Der Pluijm, Jan W Koper, B Setyonohan, D J Kwekkeboom, M P Hazenberg, S W J Lamberts
    Abstract:

    We evaluated the potential usefulness of a new radiolabeled substance P (SP) analog, [ 111 ln-DTPA-Arg 1 ]SP, as a radiopharmaceutical for the in vivo detection of SP receptor-positive (SPR+) immunologic disorders (i.e., inflammatory bowel disease and arthritis) and tumors (i.e., carcinoid). Methods : Substance P, [DTPA-Arg 1 ]SP and [3-(p-hydroxyphenyl)propionyl-Arg 1 ]SP (Bolton-Hunter-SP, [BH-SP]) were tested as competitors for 125 I-BH-SP to SPR in rat brain cortex membranes. An autoradiographic displacement study of the submandibular gland of the rat with the 125 I-BH-SP as radioligand and [DTPA-Arg 1 ]SP as competitor was performed. Tissue distribution and ex vivo autoradiography were studied in rats, with and without pretreatment with the selective nonpeptide antagonist CP96,345 to quantify specific binding. In vivo metabolism of [ 111 ln-DTPA-Arg 1 ]SP was performed in control rats. Gamma-camera scintigraphic studies were carried out with control rats to visualize the SPR+ salivary glands in rats bearing the SPR+ transplantable pancreatic tumor CA20948 and in rats with SPR+ adjuvant arthritic joints, which was induced after injection of a homogenate of Mycobacterium tuberculosis. Results : Substance P, [DTPA-Arg 1 ]SP and BH-SP dose-dependently inhibited binding of 125 I-BH-SP to SPR in rat brain cortex membranes with IC 50 values of 0.2, 4 and 2 nM, respectively. In an autoradiographic displacement study of the submandibular gland with 125 I-BH-SP as radioligand, an IC 50 of 2.7 nM was found for [DTPA-Arg 1 ]SP. In vivo metabolism of the radiopharmaceutical in the rat revealed a renal clearance rate of 50% of the injected radioactive dose in 30 min and a rapid enzymatic degradation of the radiopharmaceutical, resulting in an effective half-life of the intact radiopharmaceutical in blood of approximately 3 min. Tissue distribution and ex vivo autoradiographic studies in rats showed uptake and specific binding of radioactivity in isolated tumors and submandibular and parotid glands. Optimum SPR+ target-to-background ratios were found 24 hr after injection of [ 111 ln-DTPA-Arg 1 ]SP. Visualization of normal SPR+ tissues, such as the salivary glands by gamma camera scintigraphy, after administration of [ 111 ln-DTPA-Arg 1 ]SP was demonstrated in untreated rats. Pathological SPR+ processes were visualized both in rats bearing the transplantable pancreatic tumor CA20948 and in those with adjuvant mycobacteria tuberculosis-induced arthritic joints. Conclusion : [Indium-111-DTPA-Arg 1 ]SP can be used successfully to visualize SPR+ processes in vivo by gamma camera scintigraphy.